Clinical and Laboratory Findings in ET Patients and Results of Clonality Analysis Using mRNA Genes
No. . | Age at Diagnosis . | Follow-up Time . | Treatment . | C.S . | Unfractionated Blood . | T-Lymphocyte Fraction . | Granulocyte Fraction . | Platelets . | Platelet Counts at Diagnosis ×109/L . |
---|---|---|---|---|---|---|---|---|---|
14-150 | 36 | 53 | Hydrea | + | MO | MO | MO | MO | 1,100 |
24-150 | 34 | 148 | Hydrea | + | MO | MO | MO | MO | 889 |
34-150 | 37 | 77 | Interferon | − | MO | PO | MO | MO | 2,160 |
44-150 | 80 | 18 | Hydrea | + | MO | PO | MO | MO | 812 |
5 | 21 | 1 | 0 | − | MO | PO | MO | MO | 1,886 |
6 | 50 | 57 | Hydrea | + | MO | PO | MO | MO | 1,700 |
74-150 | 33 | 34 | Hydrea | − | MO | PO | MO | MO | 1,750 |
84-150 | 65 | 49 | Hydrea | − | MO | PO | MO | MO | 803 |
94-150 | 55 | 100 | Hydrea | + | MO | PO | MO | MO | 800 |
10 | 75 | 52 | Hydrea | − | MO | PO | MO | MO | 710 |
11 | 57 | 98 | Hydrea | − | MO | PO | MO | MO | 800 |
12 | 71 | 1 | 0 | − | MO | PO | MO | MO | 1,150 |
13 | 69 | 2 | 0 | − | MO | PO | MO | MO | 900 |
14 | 69 | 12 | Hydrea | + | MO | PO | MO | MO | 2,000 |
15 | 39 | 1 | 0 | − | MO | PO | MO | MO | 1,400 |
16 | 77 | 1 | 0 | + | MO | PO | MO | MO | 650 |
17 | 69 | 48 | 0 | − | MO | PO | MO | MO | 787 |
184-150 | 65 | 38 | Hydrea | − | MO | PO | MO | MO | 745 |
194-150 | 48 | 24 | Hydrea | − | MO | PO | MO | MO | 1,069 |
20 | 63 | 123 | Hydrea | − | MO | PO | MO | MO | 950 |
214-150 | 59 | 120 | Hydrea | − | MO | PO | MO | MO | 768 |
22 | 38 | 1 | 0 | − | PO | PO | PO | MO | 674 |
23 | 63 | 1 | 0 | + | PO | PO | PO | MO | 1,200 |
244-150 | 71 | 1 | 0 | − | PO | PO | PO | MO | 751 |
25 | 24 | 124 | 0 | − | PO | PO | PO | PO | 950 |
264-150 | 25 | 59 | 0 | − | PO | PO | PO | PO | 751 |
27 | 25 | 336 | 0 | − | PO | PO | PO | PO | 780 |
28 | 43 | 132 | 0 | − | PO | PO | PO | PO | 600 |
29 | 30 | 85 | Hydrea | + | PO | PO | PO | PO | 648 |
30 | 37 | 108 | Interferon | − | PO | PO | PO | PO | 1,098 |
31 | 76 | 50 | Hydrea | + | PO | PO | PO | PO | 660 |
No. . | Age at Diagnosis . | Follow-up Time . | Treatment . | C.S . | Unfractionated Blood . | T-Lymphocyte Fraction . | Granulocyte Fraction . | Platelets . | Platelet Counts at Diagnosis ×109/L . |
---|---|---|---|---|---|---|---|---|---|
14-150 | 36 | 53 | Hydrea | + | MO | MO | MO | MO | 1,100 |
24-150 | 34 | 148 | Hydrea | + | MO | MO | MO | MO | 889 |
34-150 | 37 | 77 | Interferon | − | MO | PO | MO | MO | 2,160 |
44-150 | 80 | 18 | Hydrea | + | MO | PO | MO | MO | 812 |
5 | 21 | 1 | 0 | − | MO | PO | MO | MO | 1,886 |
6 | 50 | 57 | Hydrea | + | MO | PO | MO | MO | 1,700 |
74-150 | 33 | 34 | Hydrea | − | MO | PO | MO | MO | 1,750 |
84-150 | 65 | 49 | Hydrea | − | MO | PO | MO | MO | 803 |
94-150 | 55 | 100 | Hydrea | + | MO | PO | MO | MO | 800 |
10 | 75 | 52 | Hydrea | − | MO | PO | MO | MO | 710 |
11 | 57 | 98 | Hydrea | − | MO | PO | MO | MO | 800 |
12 | 71 | 1 | 0 | − | MO | PO | MO | MO | 1,150 |
13 | 69 | 2 | 0 | − | MO | PO | MO | MO | 900 |
14 | 69 | 12 | Hydrea | + | MO | PO | MO | MO | 2,000 |
15 | 39 | 1 | 0 | − | MO | PO | MO | MO | 1,400 |
16 | 77 | 1 | 0 | + | MO | PO | MO | MO | 650 |
17 | 69 | 48 | 0 | − | MO | PO | MO | MO | 787 |
184-150 | 65 | 38 | Hydrea | − | MO | PO | MO | MO | 745 |
194-150 | 48 | 24 | Hydrea | − | MO | PO | MO | MO | 1,069 |
20 | 63 | 123 | Hydrea | − | MO | PO | MO | MO | 950 |
214-150 | 59 | 120 | Hydrea | − | MO | PO | MO | MO | 768 |
22 | 38 | 1 | 0 | − | PO | PO | PO | MO | 674 |
23 | 63 | 1 | 0 | + | PO | PO | PO | MO | 1,200 |
244-150 | 71 | 1 | 0 | − | PO | PO | PO | MO | 751 |
25 | 24 | 124 | 0 | − | PO | PO | PO | PO | 950 |
264-150 | 25 | 59 | 0 | − | PO | PO | PO | PO | 751 |
27 | 25 | 336 | 0 | − | PO | PO | PO | PO | 780 |
28 | 43 | 132 | 0 | − | PO | PO | PO | PO | 600 |
29 | 30 | 85 | Hydrea | + | PO | PO | PO | PO | 648 |
30 | 37 | 108 | Interferon | − | PO | PO | PO | PO | 1,098 |
31 | 76 | 50 | Hydrea | + | PO | PO | PO | PO | 660 |
Follow-up (months) at the time of clonality analysis.
Abbreviations: C.S, ischemic or hemorrhagic symptoms; MO, monoclonal; PO, polyclonal; RNA genes, G6PD or IDS or P55.
Patients reported in our previous study.14